Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 3 3Phase NA 2Phase 1 2

Status

Withdrawn 2Completed 2Unknown 1

Sponsor Class

NIH 3OTHER 2

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 5Dermatologic 4Breast 4Thoracic 3Other hematologic neoplasm 3Lymphoid 3Sarcoma 2Head & Neck 2Plasma cell 1Other solid neoplasm 1Myeloid 1Endocrine 1CNS 1

Conditions

Rectal Neoplasms 3Colorectal Neoplasms 3Colonic Neoplasms 2Pancreatic Neoplasms 1Neurotoxicity Syndromes 1Neoplasm Metastasis 1Gallbladder Neoplasms 1Carcinoma, Hepatocellular 1Bile Duct Neoplasms 1

Interventions

Oxaliplatin 780Fluorouracil 638Capecitabine 575Gemcitabine 478Leucovorin 459Bevacizumab 445Irinotecan 444Cisplatin 338Radiotherapy 283Cetuximab 252Paclitaxel 180S 1 (combination) 176pembrolizumab 173Docetaxel 156Drug Therapy 147Nivolumab 146sintilimab 143tislelizumab 131apatinib 131130-nm albumin-bound paclitaxel 128Folfox protocol 121durvalumab 119Albumin-Bound Paclitaxel 117camrelizumab 107lenvatinib 106Panitumumab 106regorafenib 102Surgical Procedures, Operative 102Sorafenib 99Radiation 88

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × Pharmacogenomic Testing × Gastrointestinal × Clear all
NCT00936832 2022-08-30

Sunitinib Malate and Combination Chemotherapy as Front-Line Therapy in Treating Patients With Metastatic Rectal Cancer That Cannot Be Removed by Surgery

Federation Francophone de Cancerologie Digestive

Phase 2 Withdrawn
Gastrointestinal

Neoplasm Metastasis, Rectal Neoplasms, Colorectal Neoplasms

NCT00735917 2019-04-02

Saracatinib in Treating Patients With Previously Treated Metastatic Pancreatic Cancer

National Cancer Institute (NCI)

Phase 2 Completed
19 enrolled 7 charts
Gastrointestinal

Pancreatic Neoplasms

NCT01859182 2014-09-09

Selumetinib and Akt Inhibitor MK-2206 in Treating Patients With Refractory or Advanced Gallbladder or Bile Duct Cancer That Cannot Be Removed By Surgery

National Cancer Institute (NCI)

Phase 2 Withdrawn
Gastrointestinal

Bile Duct Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular

NCT01205711 2014-07-08

FOLFERA

Cardiff University

Phase 2 Completed
111 enrolled
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT00884767 2009-07-08

Biomarkers in Predicting Neurotoxicity in Patients With Colorectal Cancer Receiving Oxaliplatin

National Cancer Institute (NCI)

Phase 2 Unknown
206 enrolled
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Neurotoxicity Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡